Renal cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Renal cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Subcutaneous Nivolumab for Patients with Previously Treated Advanced or Metastatic Clear Cell Kidney Cancer https://clinicaltrials.eu/trial/study-of-subcutaneous-nivolumab-for-patients-with-previously-treated-advanced-or-metastatic-clear-cell-kidney-cancer/ Wed, 29 Apr 2026 15:01:12 +0000 https://clinicaltrials.eu/trial/study-of-subcutaneous-nivolumab-for-patients-with-previously-treated-advanced-or-metastatic-clear-cell-kidney-cancer/ This clinical trial is focused on studying a type of kidney cancer known as advanced or metastatic clear cell renal cell carcinoma. This is a condition where cancer cells form in the lining of the tubules in the kidney and have spread to other parts of the body. The study is investigating a treatment called nivolumab, which is a medication that helps the immune system fight cancer. Nivolumab is being tested in two forms: one that is given through a vein, known as intravenous nivolumab, and another that is injected under the skin, called subcutaneous nivolumab. The subcutaneous form is also referred to by its code name, BMS-986298.

The purpose of this study is to compare the effectiveness of the subcutaneous form of nivolumab to the intravenous form in patients who have already received other treatments for their cancer. Participants in the study will be randomly assigned to receive either the subcutaneous or intravenous form of nivolumab. The study will monitor how the medication is processed in the body and its effects on the cancer over time. Some participants may receive a placebo, which is a substance with no active medication, to help compare the results.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of their cancer. The study aims to provide valuable information on whether the subcutaneous form of nivolumab is as effective as the intravenous form, potentially offering a more convenient treatment option for patients with advanced kidney cancer. The study is expected to continue for several years to gather comprehensive data on the treatment’s long-term effects and safety.

]]> Study on the Safety and Effects of Temferon for Patients with Metastatic Renal Cell Carcinoma Using a Drug Combination https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-temferon-for-patients-with-metastatic-renal-cell-carcinoma-using-a-drug-combination/ Wed, 29 Apr 2026 14:58:55 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-temferon-for-patients-with-metastatic-renal-cell-carcinoma-using-a-drug-combination/ This clinical trial is focused on studying a treatment for patients with metastatic renal cell carcinoma, a type of kidney cancer that has spread to other parts of the body. The treatment being tested is called Temferon. Temferon is a gene therapy that uses a patient’s own blood stem cells, which are modified to produce a protein called interferon alpha-2. This protein is known to help the immune system fight cancer. The study will also involve other medications, including Cabozantinib, Busulfan, Pembrolizumab, Plerixafor, and Lenograstim, which are used to prepare the body for the gene therapy and support the treatment process.

The purpose of this study is to evaluate the safety and biological response of Temferon in patients with metastatic renal cell carcinoma. Participants will receive a single dose of Temferon, and the study will monitor how well the treatment is tolerated and how it affects the cancer. The study will also look at the presence of modified cells in the blood and bone marrow, as well as any changes in the cancer’s progression. Patients will be closely observed for any side effects or adverse reactions to the treatment.

Throughout the study, participants will undergo regular medical check-ups and laboratory tests to ensure their safety and to assess the effectiveness of the treatment. The study aims to provide valuable information on the potential benefits of Temferon for patients with metastatic renal cell carcinoma, with the hope of improving treatment options for this challenging condition.

]]> Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment https://clinicaltrials.eu/trial/study-on-cabozantinib-nivolumab-and-ipilimumab-for-patients-with-advanced-or-metastatic-kidney-cancer-who-have-not-received-prior-treatment/ Wed, 29 Apr 2026 14:23:06 +0000 https://clinicaltrials.eu/trial/study-on-cabozantinib-nivolumab-and-ipilimumab-for-patients-with-advanced-or-metastatic-kidney-cancer-who-have-not-received-prior-treatment/ This clinical trial is focused on studying a type of kidney cancer known as Metastatic Renal Cell Carcinoma (RCC), which is an advanced form of cancer that has spread beyond the kidney. The study is investigating the effectiveness and safety of a combination of medications in patients who have not received prior treatment for this condition. The medications being tested include Cabozantinib, Nivolumab, and Ipilimumab. Cabozantinib is taken as a tablet, while Nivolumab and Ipilimumab are given as infusions, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to compare the combination of Cabozantinib, Nivolumab, and Ipilimumab against the combination of Nivolumab and Ipilimumab alone. Participants will be randomly assigned to receive either the three-drug combination or the two-drug combination. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know which treatment each participant is receiving, to ensure unbiased results. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients.

The study will take place over a period of time, with regular visits to monitor the participants’ health and the effects of the treatment. The main goal is to see how long the participants live without the cancer getting worse, known as Progression-Free Survival (PFS). The study will also look at overall survival, which is the length of time participants live after starting the treatment. Participants will be closely monitored for any side effects or changes in their condition throughout the study.

]]> Study on the Effectiveness of Atezolizumab with Radiotherapy for Patients with Metastatic Colorectal, Lung, Renal, and Sarcoma Cancers https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-atezolizumab-with-radiotherapy-for-patients-with-metastatic-colorectal-lung-renal-and-sarcoma-cancers/ Wed, 29 Apr 2026 14:22:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-atezolizumab-with-radiotherapy-for-patients-with-metastatic-colorectal-lung-renal-and-sarcoma-cancers/ This clinical trial is focused on studying the effects of a treatment for patients with metastatic tumors, which are cancers that have spread to other parts of the body. The specific types of cancer being studied include colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and sarcoma. The treatment being tested combines a medication called atezolizumab with a type of radiation therapy known as stereotactic ablative radiotherapy (SABR). Atezolizumab is an anti-PD-L1 antibody, which is a type of protein designed to help the immune system fight cancer cells.

The purpose of this study is to evaluate how effective this combination treatment is in preventing the cancer from getting worse over a period of one year. During the study, patients will receive atezolizumab through an intravenous (IV) infusion, which means the medication is given directly into a vein. They will also undergo SABR, a precise form of radiation therapy that targets the cancer cells while minimizing damage to surrounding healthy tissue. The study will monitor patients’ health and the progression of their cancer over time.

Participants in the study will be observed to see if the treatment helps keep their cancer from progressing and to assess any side effects they may experience. The study aims to provide valuable information on the potential benefits and risks of using atezolizumab in combination with SABR for treating metastatic tumors. This research could contribute to developing more effective treatment options for patients with these types of cancer.

]]>